NCT07241065 is a Phase 1 clinical trial of Dextromethorphan in Healthy Participants, sponsored by AstraZeneca.

Who is sponsoring NCT07241065?

NCT07241065 is sponsored by AstraZeneca.

What drugs are being tested in NCT07241065?

Interventions in NCT07241065: Dextromethorphan, Capivasertib.

What condition does NCT07241065 study?

NCT07241065 studies Healthy Participants.

Is NCT07241065 still recruiting?

NCT07241065 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT07241065

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

Recruiting now Phase 1 Last updated 15 April 2026

What this trial tests

Phase 1 trial testing Dextromethorphan in Healthy Participants in 42 participants. Currently enrolling.

Timeline

19 March 2026

Primary endpoint
17 June 2026

17 June 2026

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	other
Enrollment	42
Start date	19 March 2026
Primary completion	17 June 2026
Estimated completion	17 June 2026
Sites	1 location across Germany

Drugs / interventions tested

Dextromethorphan — full drug profile →
Capivasertib — full drug profile →

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 60, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the effect of capivasertib on the pharmacokinetics of oral dextromethorphan in healthy participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Dextromethorphan

Trials testing the same drug.

NCT05068791 — Psilocybin-facilitated Treatment for Chronic Pain · EARLY_PHASE1 · recruiting
NCT05944510 — Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia · Phase 4 · completed
NCT05699993 — A Study of IBI351 in Healthy Subjects · Phase 1 · completed
NCT05947604 — DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan · Phase 1 · completed
NCT05602675 — A Drug Interaction Study of LY3871801 in Healthy Participants · Phase 1 · completed

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07241065 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07241065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing